Mizuho Reiterates Buy Rating on Biogen Inc. (BIIB)
Mizuho keeps its buy rating on Biogen Inc., setting a $221 price target.
Key Points
- On June 15, 2026, Mizuho reiterated its buy rating for Biogen Inc., setting a price target of $221.
- Biogen Inc. trades at $200.05 with a market cap of $29.53 billion and a P/E ratio of 21.51.
- Insiders, including Menelas Pangalos, recently bought shares, while analysts like Needham upgraded Biogen to buy.
Mizuho has reaffirmed its confidence in Biogen Inc. by maintaining a buy rating and setting a price target of $221. This update was made on June 15, 2026, by analyst Salim Syed. Shares of Biogen were trading at $200.05 around this time.
Other Institutional Activity in Biogen
Several institutional investors have also been active in Biogen. BlackRock, Inc. increased its holdings by 1,163,231 shares, bringing its total to 15,974,601 shares valued at approximately $2.93 billion. FMR LLC made a significant addition of 3,381,678 shares, resulting in a total of 12,807,541 shares worth about $2.35 billion. State Street Corp added 8,902 shares, ending with 7,167,922 shares valued at $1.31 billion.
Biogen Inc. Stock Snapshot
Shares of Biogen Inc. (NasdaqGS: BIIB) recently traded at $200.05. The company boasts a market capitalization of $29.53 billion and a P/E ratio of 21.51, with a forward P/E of 11.99. Its beta is quite low at 0.177, indicating less volatility compared to the broader market. The stock's 52-week range is between $121.05 and $205.97, with a 50-day moving average of $188.79 and a 200-day moving average of $173.46. Biogen maintains a strong financial position with a current ratio of 3.07 and a quick ratio of 2.03.
Recent Earnings
Biogen reported revenue of approximately $9.94 billion, with a modest growth rate of 1.9%. The company's net margin stands at 13.81%, and it achieved a return on equity of 7.7%. The next earnings report is expected on July 30, 2026.
Insider Buying and Selling at Biogen Inc.
Recent insider activity at Biogen includes several purchases on June 9, 2026. Notable transactions include Menelas Pangalos buying 2,370 shares, Eric Rowinsky purchasing 1,505 shares, and Stephen Sherwin also acquiring 1,505 shares. These transactions were not part of any pre-planned trading programs.
Analysts Set New Price Targets
In addition to Mizuho's reiteration, Needham upgraded Biogen to a buy on June 8, 2026, with a target price of $255. RBC Capital maintained its buy rating on May 27, 2026, with a target of $227. The consensus among 30 analysts is a buy, with an average target price of $220.13.
About Biogen Inc.
Biogen Inc., headquartered in Cambridge, Massachusetts, is a major player in the healthcare sector, specifically within the drug manufacturing industry. The company is known for discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Under the leadership of CEO Christopher A. Viehbacher, Biogen employs around 7,500 people and offers treatments for conditions like multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease.
Bottom Line
Mizuho's reaffirmation of its buy rating for Biogen Inc. underscores the investment community's interest in the company's potential. While this rating reflects past analysis, investors often track such updates for insights into market sentiment and potential stock movements. As always, it's important to remember that these ratings are backward-looking and may not necessarily predict future performance.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.